Evidence map›Paper›PMID 37904255›Full record

ReviewDiabetology & metabolic syndrome2023

Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

Qian Zhou, Xingxing Lei, Shunlian Fu, Pan Liu, Cong Long, Yanmei Wang, Zinan Li, Qian Xie, Qiu Chen

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetology & metabolic syndrome, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Achieving BMI <25 kg/mEClinicalMedicine · 2026
    Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Qian ZhouHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan, China.ORCID http://orcid.org/0000-0001-6957-9821
Xingxing LeiHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan, China.
Shunlian FuHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan, China.
Pan LiuHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan, China.
Cong LongHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan, China.
Yanmei WangYa'an Polytechnic College Affiliated Hospital, Ya'an, China.
Zinan LiHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan, China.
Qian XieHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan, China.
Qiu ChenHospital of Chengdu University of Traditional Chinese Medicine, No. 39, Shi-er-Qiao Road, Chengdu, 610072, Sichuan Province, People's Republic of China. chenqiu1005@cdutcm.edu.cn.
Chengdu University of Traditional Chinese Medicine · CNSichuan Integrative Medicine Hosipital · CNYa'an Polytechnic College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are the main incretin hormones, and be responsible for the insulinotropic incretin effect. The addition of a GIP agonist to a GLP-1agonist has been hypothesized to significantly potentiate the weight-losing and glycemia control effect, which might offer a new therapeutic option in the treatment of type 2 diabetes. The current meta-analysis aims to synthesize evidence of primary efficacy and safety outcomes through clinically randomized controlled trials to evaluate integrated potency and signaling properties.

methodWe conducted comprehensive literature searches in Cochrane Library, Web of Science, Embase and PubMed for relevant literatures investigating the efficacy and/or safety of Tirzepatide published in the English as of May 30, 2023 was retrieved. We synthesized results using standardized mean differences (SMDs) and 95% confidence intervals (95 CIs) for continuous outcomes, and odds ratios (ORs) along with 95 Cis for dichotomous outcomes. All analyses were done using Revman version 5.3, STATA version 15.1 and the statistical package 'meta'.

resultsParticipants treated with weekly Tirzepatide achieved HbA1c and body weight target values significantly lower than any other comparator without clinically significant increase in the incidence of hypoglycemic events, serious and all-cause fatal adverse events. However, gastrointestinal adverse events and decreased appetite events were reported more frequently with Tirzepatide treatment than with placebo/controls.

conclusionThe Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, for diabetes therapy has opened a new era on personalized glycemia control and weight loss in a safe manner with broad and promising clinical implications.

Indexed as

Dual GIP/GLP-1 receptor agonistGLP-1 receptor agonistsMeta-analysisTirzepatideType 2 diabetes

Identifiers

PMID37904255
PMCPMC10614386
OpenAlexW4388034622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.